A Phase 3 interventional study of Palbociclib and Letrozole in Breast Neoplasms, sponsored by Pfizer. Completed at 54 sites in 5 countries. Open to female participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-11-05.
Sponsored by Pfizer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 111 studies testing palbociclib in Breast Neoplasms — 19 open to participants now, 43 under way, 9 of them phase 3. palbociclib · Breast Neoplasms.
Among the 111 studies testing palbociclib in Breast Neoplasms, this one is the 23rd largest by enrollment, is one of 13 that started in 2015, is one of 20 in phase 3, and was the 18th registered.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.
Browse Breast Neoplasms studies →19 of the 111 studies testing palbociclib in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:
Fudan University · Sites in China
Ages 18+
American Society of Clinical Oncology · Sites in United States
Ages 60+
Region Örebro County · Sites in Finland, Greece, Italy and 3 more countries
Ages 70+
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest · Sites in Germany
Ages 18+ · Women only
Northwestern University · Sites in United States
Ages 18+
By country, each count listing its studies:
palbociclib: first FDA approval 2015 (IBRANCE), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →
Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.
This study: 18 Years to 70 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, palbociclib is the treatment under test here. Read study by study →
111 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 19 · Phase 2 68 · Phase 3 21 · Phase 4 5
First in 2008; this study’s year is marked. 13 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 340 is above the median of 72 across 10,908 interventional studies indexed under Breast Neoplasms.
Median enrollment 100 across the 111 interventional studies. Of the 54 that completed or were terminated, 27 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 111 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
182 studies in Breast Neoplasms by Pfizer: 6 open now, 26 under way, 7 of them phase 3. Of 145 finished, 94 (65%) have results posted.
Among the 182 studies in Breast Neoplasms by Pfizer, this one is the 23rd largest by enrollment of the 121 interventional ones that give a count, is one of 3 that started in 2015, is one of 25 in phase 3, and was the 85th registered.
Pfizer’s Breast Neoplasms studies by the year they started, since 1998.
13 of the studies testing palbociclib in Breast Neoplasms that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03820830Phase 3ETOP IBCSG Partners FoundationPalbociclib for HR Positive / HER2-negative Isolated Locoregional Recurrence of Breast Cancer | 2026-12 |
| NCT02605486Memorial Sloan Kettering Cancer CenterPalbociclib in Combination With Bicalutamide for the Treatment of AR(+) Metastatic Breast Cancer (MBC) | 2026-11 |
| NCT02738866Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsPalbociclib With Fulvestrant for Metastatic Breast Cancer After Treatment With Palbociclib and an Aromatase Inhibitor | 2026-12 |
| NCT07130643Xinhong Wu, PhDEfficacy and Safety of CDK4/6 Inhibitors Combined With Endocrine Therapy in HR+/HER2- Neoadjuvant Therapy for Early Breast Cancer | 2026-12-20 |
| NCT03573648Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNeoadjuvant Endocrine Therapy, Palbociclib, Avelumab in Estrogen Receptor Positive Breast Cancer | 2026-12-30 |
Add all 13 to your calendar (.ics) → With an account.
Among the 111 studies testing palbociclib in Breast Neoplasms, from their registry updates:
Among Pfizer’s 182 in Breast Neoplasms:
This tab as a report to print or save as PDF → With an account.
The study is designed to compare the clinical benefit following treatment with letrozole in combination with Palbociclib versus letrozole in combination with placebo in Asian postmenopausal women with ER(+)/HER2(-) advanced breast cancer who have not received prior systemic anti cancer therapies for their advanced/metastatic disease.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Palbociclib, 125mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment in combination with Letrozole, 2.5mg, orally once daily (continuously)
Drug: Palbociclib · Drug: Letrozole
Placebo, 125mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment in combination with Letrozole, 2.5mg, orally once daily (continuously).
Drug: Placebo · Drug: Letrozole
Palbociclib, 125mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment
Also known as: PD-0332991
Letrozole, 2.5mg, orally once daily (continuously)
Placebo, 125mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment
Letrozole, 2.5mg, orally once daily (continuously)
Progression-Free Survival (PFS) Based on Investigator's Assessment: Up to Primary Completion Date
PFS was based on Kaplan-Meier estimates. PFS was defined as the time from the date of randomization to the date of the first documentation of objective progression of disease (PD) or death due to any cause in the absence of documented PD, whichever occurred first. PD is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) as a 20% increase in the sum of diameters of target measurable lesions above the smallest sum observed (over baseline if no decrease in the sum is observed during therapy), with a minimum absolute increase of 5 mm. In this outcome measure, PFS was based on investigator's assessment.
Time frame: Randomization up to 65 months
Progression-Free Survival (PFS) Based on Blinded Independent Central Review (BICR): Up to Primary Completion Date
PFS was based on Kaplan-Meier estimates. PFS was defined as time from the first dose of study treatment to the first documentation of objective tumor progression or to death due to any cause in the absence of documented progressive disease, whichever occurs first. In this outcome measure, PFS was based on BICR.
Time frame: Randomization up to 65 months
Percentage of Participants With Objective Response (OR) Based on Investigator Assessment: Up to Primary Completion Date
OR was defined as a complete response (CR) or partial response (PR) according to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 recorded from randomization until disease progression or death due to any cause. CR was defined as complete disappearance of all target lesions with the exception of nodal disease. All target nodes must decrease to normal size (short axis \<10 mm). No new lesions. The PR was defined as greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. The short diameter was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No new lesions. In this outcome measure, OR was based on investigator assessment.
Time frame: Randomization up to 65 months
Percentage of Participants With Objective Response (OR) Based on Investigator Assessment (Participants With Measurable Disease at Baseline): Up to Primary Completion Date
OR was defined as a complete response (CR) or partial response (PR) according to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 recorded from randomization until disease progression or death due to any cause. CR was defined as complete disappearance of all target lesions with the exception of nodal disease. All target nodes must decrease to normal size (short axis \<10 mm). No new lesions. The PR was defined as greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. The short diameter was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No new lesions. In this outcome measure, OR was based on investigator assessment.
Time frame: Randomization up to 65 months
Percentage of Participants With Objective Response (OR) Based on Blinded Independent Central Review (BICR): Up to Primary Completion Date
OR was defined as a complete response (CR) or partial response (PR) according to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 recorded from randomization until disease progression or death due to any cause. CR was defined as complete disappearance of all target lesions with the exception of nodal disease. All target nodes must decrease to normal size (short axis \<10 mm). No new lesions. The PR was defined as greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. The short diameter was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No new lesions. In this outcome measure, OR was based on BICR.
Time frame: Randomization up to 65 months
Percentage of Participants With Objective Response (OR) Based on Blinded Independent Central Review (BICR) (Participants With Measurable Disease at Baseline): Up to Primary Completion Date
OR was defined as a complete response (CR) or partial response (PR) according to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 recorded from randomization until disease progression or death due to any cause. CR was defined as complete disappearance of all target lesions with the exception of nodal disease. All target nodes must decrease to normal size (short axis \<10 mm). No new lesions. The PR was defined as greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. The short diameter was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No new lesions. In this outcome measure, OR was based on BICR.
Time frame: Randomization up to 65 months
Duration of Response (DOR) Based on Investigator Assessment (Participants With Objective Disease Response): Up to Primary Completion Date
DOR was defined as the time from the first documentation of objective tumor response (complete response \[CR\] or partial response \[PR\]) to the first documentation of objective tumor progression or to death due to any cause, whichever occurred first. DOR data was censored on the date of the last tumor assessment on study for participants who did not have objective tumor progression and who did not die due to any cause while on study. CR was defined as complete disappearance of all target lesions with the exception of nodal disease. All target nodes must decrease to normal size (short axis \<10 mm). No new lesions. The PR was defined as greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. The short diameter was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No new lesions. In this outcome measure, DOR was based on investigator assessment.
Time frame: Randomization up to 65 months
Duration of Response (DOR) Based on Blinded Independent Central Review (BICR) (Participants With Objective Disease Response): Up to Primary Completion Date
DOR was defined as the time from the first documentation of objective tumor response (complete response \[CR\] or partial response \[PR\]) to the first documentation of objective tumor progression or to death due to any cause, whichever occurred first. DOR data was censored on the date of the last tumor assessment on study for participants who did not have objective tumor progression and who did not die due to any cause while on study. CR was defined as complete disappearance of all target lesions with the exception of nodal disease. All target nodes must decrease to normal size (short axis \<10 mm). No new lesions. The PR was defined as greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. The short diameter was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No new lesions. In this outcome measure, DOR was based on BICR.
Time frame: Randomization up to 65 months
Percentage of Participants With Disease Control/Clinical Benefit Response (DC/CBR) Based on Investigator Assessment: Up to Primary Completion Date
DC/CBR was defined as CR, PR, or stable disease (SD) \>=24 weeks according to the Response Evaluation Criteria in Solid Tumors (RECIST v1.1) recorded in the time period between randomization and disease progression or death to any cause. CR was defined as complete disappearance of all target lesions except for nodal disease. All target nodes must decrease to normal size (short axis \<10 mm). No new lesions. The PR was defined as \>=30% decrease under baseline of the sum of diameters of all target measurable lesions. The short diameter was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No new lesions. SD was defined as not qualifying for CR, PR, PD. PD is defined using RECIST v1.1 as a 20% increase in the sum of diameters of target measurable lesions above the smallest sum observed, with a minimum absolute increase of 5 mm. In this outcome measure, DC/CBR was based on investigator assessment.
Time frame: Randomization up to 65 months
Percentage of Participants With Disease Control/Clinical Benefit Response (DC/CBR) Based on Investigator Assessment (Participants With Measurable Disease at Baseline): Up to Primary Completion Date
DC/CBR was defined as CR, PR, or stable disease (SD) \>=24 weeks according to the Response Evaluation Criteria in Solid Tumors (RECIST v1.1) recorded in the time period between randomization and disease progression or death to any cause. CR was defined as complete disappearance of all target lesions except for nodal disease. All target nodes must decrease to normal size (short axis \<10 mm). No new lesions. The PR was defined as greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. The short diameter was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No new lesions. SD was defined as not qualifying for CR, PR, PD. PD is defined using RECIST v1.1 as a 20% increase in the sum of diameters of target measurable lesions above the smallest sum observed, with a minimum absolute increase of 5 mm. In this outcome measure, DC/CBR was based on investigator assessment.
Time frame: Randomization up to 65 months
Percentage of Participants With Disease Control/Clinical Benefit Response (DC/CBR) Based on Blinded Independent Central Review (BICR): Up to Primary Completion Date
DC/CBR was defined as CR, PR, or stable disease (SD) \>=24 weeks according to the Response Evaluation Criteria in Solid Tumors (RECIST v1.1) recorded in the time period between randomization and disease progression or death to any cause. CR was defined as complete disappearance of all target lesions except for nodal disease. All target nodes must decrease to normal size (short axis \<10 mm). No new lesions. The PR was defined as greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. The short diameter was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No new lesions. SD was defined as not qualifying for CR, PR, PD. PD is defined using RECIST v1.1 as a 20% increase in the sum of diameters of target measurable lesions above the smallest sum observed, with a minimum absolute increase of 5 mm. In this outcome measure, DC/CBR was based on BICR.
Time frame: Randomization up to 65 months
Percentage of Participants With Disease Control/Clinical Benefit Response (DC/CBR) Based on Blinded Independent Central Review (BICR) (Participants With Measurable Disease at Baseline): Up to Primary Completion Date
DC/CBR was defined as CR, PR, or stable disease (SD) \>=24 weeks according to the Response Evaluation Criteria in Solid Tumors (RECIST v1.1) recorded in the time period between randomization and disease progression or death to any cause. CR was defined as complete disappearance of all target lesions except for nodal disease. All target nodes must decrease to normal size (short axis \<10 mm). No new lesions. The PR was defined as greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. The short diameter was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No new lesions. SD was defined as not qualifying for CR, PR, PD. PD is defined using RECIST v1.1 as a 20% increase in the sum of diameters of target measurable lesions above the smallest sum observed, with a minimum absolute increase of 5 mm. In this outcome measure, DC/CBR was based on BICR.
Time frame: Randomization up to 65 months
Overall Survival (OS): Up to Primary Completion Date
OS was defined as the time from date of randomization to date of death due to any cause. In the absence of confirmation of death, survival time was censored to last date the participant was known to be alive. OS was assessed using Kaplan-Meier methods.
Time frame: Randomization up to 65 months
1-Year, 2-Year and 3-Year Survival Probability: Up to Primary Completion Date
OS was defined as the time from date of randomization to date of death due to any cause. In the absence of confirmation of death, survival time was censored to last date the participant was known to be alive. The 1-year survival probability was estimated using the Kaplan-Meier method and a 2-sided 95% confidence interval (CI) for the log \[-log(1 year survival probability)\] was be calculated using a normal approximation, and then back transformed to give a CI for the 1-year survival probability itself. The 2-year, and 3-year survival probabilities were estimated similarly.
Time frame: Randomization up to 65 months
Number of Participants With Treatment-Emergent Adverse Events (All Causalities): Up to Primary Completion Date
An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious AE (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state. Participants were counted only once per treatment in each row.
Time frame: Randomization up to 65 months
Number of Participants With Treatment-Emergent Adverse Events (Treatment Related): Up to Primary Completion Date
An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious AE (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state. Relatedness to treatment was assessed by the investigator (Yes/No). Participants were counted only once per treatment in each row.
Time frame: Randomization up to 65 months
Number of Participants With Postbaseline Laboratory Abnormalities of Common Terminology Criteria for Adverse Events (CTCAE) Grade 3 or 4 (Participants With Baseline Laboratory Abnormalities of CTCAE Grade <=2) - Hematology: Up to Primary Completion Date
The laboratory results were graded according to the National Cancer Institute (NCI) CTCAE v4.0 severity grade. Shift tables were provided to examine the distribution of laboratory toxicities. The following hematology parameters had met the criteria of CTCAE grade shift change from Grade \<=2 at baseline to Grade 3 or 4 post baseline: neutrophils (absolute), white blood cells, platelets, anemia and hemoglobin increased.
Time frame: Randomization up to 65 months
Number of Participants With Postbaseline Laboratory Abnormalities of Common Terminology Criteria for Adverse Events(CTCAE) Grade 3 or 4 (Participants With Baseline Laboratory Abnormalities of CTCAE Grade <=2) - Chemistry: Up to Primary Completion Date
The laboratory results were graded according to the National Cancer Institute (NCI) CTCAE v4.0 severity grade. Shift tables were provided to examine the distribution of laboratory toxicities. The following chemistry parameters had met the criteria of CTCAE grade shift change from Grade \<=2 at baseline to Grade 3 or 4 post baseline: alanine aminotransferase (ALT), alkaline phosphatase, aspartate aminotransferase (AST), bilirubin (total), creatinine, hypercalcemia, hyperglycemia, hyperkalemia, hypermagnesemia, hypernatremia, hypoalbuminemia, hypocalcemia, hypoglycemia, hypokalemia, hypomagnesemia, and hyponatremia.
Time frame: Randomization up to 65 months
Trough Plasma Concentration of Palbociclib
Summary of palbociclib trough concentrations.
Time frame: Pre-dose on Day 14 of Cycle 1 and Cycle 2
Model Estimated Mean Changes From Baseline in Functional Assessment of Cancer Therapy - Breast (FACT-B) Total Score: Up to Primary Completion Date
The Functional Assessment of Cancer Therapy (FACT) is a modular approach to assess participant health related quality of life using a "core" set of questions (FACT-G) as well as a cancer site specific module. The FACT-G was a 27-item compilation of general questions divided into 4 domains: Physical Well Being, Social/Family Well Being, Emotional Well Being, and Functional Well Being. The FACT-B consists of the FACT-G (27 items) and a breast specific module: a 10-item instrument designed to assess participant concerns relating to breast cancer. For all questions, participants were asked to respond to a 5-level scale ranging from 0=Not at all to 4=Very much. FACT-B total score = FACT-G + Breast Cancer Subscale. As each of the items ranges from 0-4, the range of possible scores is 0-148, with 0 being the worst possible score and 148 the best. A positive change of the total score indicated improvement from baseline and a negative change indicated deterioration.
Time frame: Baseline up to Cycle 65 Day 1
Model Estimated Mean Change From Baseline in Euro Quality of Life 5-Dimension Scale (EQ-5D) Index Scores: Up to Primary Completion Date
The EQ-5D is a 6-item instrument designed to assess health status in terms of a single index value or utility score. It consists of 5 descriptors of current health state (mobility, self care, usual activities, pain/discomfort, and anxiety/depression); a participant was asked to rate each state on a 3 level scale (1=no problem, 2=some problem, and 3=extreme problem) with higher levels indicating greater severity/impairment.
Time frame: Baseline up to Cycle 65 Day 1
Model Estimated Mean Change From Baseline in Euro Quality of Life (EQ) Visual Analog Scale (VAS) Scores: Up to Primary Completion Date
The EQ VAS recorded the participant's self rated questionnaire to assess generic health status on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state). Published weights were available that allow for the creation of a single summary score.
Time frame: Baseline up to Cycle 65 Day 1
Median Baseline Percent (%) Positive Cells for Ki67
Archived formalin-fixed paraffin embedded (FFPE) specimen from the original diagnostic tumor tissue was collected and sent to the sponsor-designated central laboratories for assessment of Ki67 associated with sensitivity and/or resistance to Palbociclib.
Time frame: Baseline
Number of Participants With Detection in Estrogen Receptor (ER)
Archived formalin-fixed paraffin embedded (FFPE) specimen from the original diagnostic tumor tissue was collected and sent to the sponsor-designated central laboratories for assessment of ER associated with sensitivity and/or resistance to Palbociclib.
Time frame: Baseline
Overall Survival: Up to Secondary Completion Date
OS was defined as the time from date of randomization to date of death due to any cause. In the absence of confirmation of death, survival time was censored to last date the participant was known to be alive. OS was assessed using Kaplan-Meier methods.
Time frame: Randomization up to 65 months
Number of Participants With Treatment-Emergent Adverse Events (All Causalities): Up to Secondary Completion Date
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state.
Time frame: Up to 28 days after last dose of study drug or start of new treatment (data collection maximum up to approximately 119 months after randomization)
Number of Participants With Treatment-Emergent Adverse Events (Treatment Related): Up to Secondary Completion Date
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state. Relatedness to treatment was assessed by the investigator (Yes/No). Participants were counted only once per treatment in each row.
Time frame: Up to 28 days after last dose of study drug or start of new treatment (data collection maximum up to approximately 119 months after randomization)
Number of Participants With Postbaseline Laboratory Abnormalities of Common Terminology Criteria for Adverse Events (CTCAE) Grade 3 or 4 (Participants With Baseline Laboratory Abnormalities of CTCAE Grade <=2) - Hematology: Up to Secondary Completion Date
The laboratory results were graded according to the NCI CTCAE v4.0 severity grade. Shift data were provided to examine the distribution of laboratory toxicities. The following hematology parameters met the criteria of CTCAE grade shift change from Grade \<=2 at baseline to Grade 3 or 4 post baseline: neutrophils (absolute), white blood cells, platelets, anemia and hemoglobin increased.
Time frame: Up to 28 days after last dose of study drug or start of new treatment (data collection maximum up to approximately 119 months after randomization)
Number of Participants With Postbaseline Laboratory Abnormalities of Common Terminology Criteria for Adverse Events (CTCAE) Grade 3 or 4 (Participants With Baseline Laboratory Abnormalities of CTCAE Grade <=2) - Chemistry: Up to Secondary Completion Date
The laboratory results were graded according to the NCI CTCAE v4.0 severity grade. Shift tables were provided to examine the distribution of laboratory toxicities. The following chemistry parameters had met the criteria of CTCAE grade shift change from Grade \<=2 at baseline to Grade 3 or 4 post baseline: ALT, alkaline phosphatase, AST, bilirubin (total), creatinine, hypercalcemia, hyperglycemia, hyperkalemia, hypermagnesemia, hypernatremia, hypoalbuminemia, hypocalcemia, hypoglycemia, hypokalemia, hypomagnesemia, and hyponatremia.
Time frame: Up to 28 days after last dose of study drug or start of new treatment (data collection maximum up to approximately 119 months after randomization)
| Milestone | Palbociclib + Letrozole | Placebo + Letrozole |
|---|---|---|
| Started | 169 | 171 |
| Completed | 0 | 0 |
| Not completed | 169 | 171 |
| Withdrew: Death | 102 | 126 |
| Withdrew: Lost to follow-up | 14 | 11 |
| Withdrew: Withdrawal by subject | 10 | 6 |
| Withdrew: Other | 34 | 23 |
| Withdrew: Participant refused further follow-up | 9 | 5 |
PFS was based on Kaplan-Meier estimates. PFS was defined as the time from the date of randomization to the date of the first documentation of objective progression of disease (PD) or death due to any cause in the absence of documented PD, whichever occurred first. PD is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) as a 20% increase in the sum of diameters of target measurable lesions above the smallest sum observed (over baseline if no decrease in the sum is observed during therapy), with a minimum absolute increase of 5 mm. In this outcome measure, PFS was based on investigator's assessment.
| Months | Palbociclib + Letrozole | Placebo + Letrozole |
|---|---|---|
| Progression-Free Survival (PFS) Based on Investigator's Assessment: Up to Primary Completion Date | 21.5 (16.6 to 24.9) | 13.9 (13.7 to 16.6) |
PFS was based on Kaplan-Meier estimates. PFS was defined as time from the first dose of study treatment to the first documentation of objective tumor progression or to death due to any cause in the absence of documented progressive disease, whichever occurs first. In this outcome measure, PFS was based on BICR.
| Months | Palbociclib + Letrozole | Placebo + Letrozole |
|---|---|---|
| Progression-Free Survival (PFS) Based on Blinded Independent Central Review (BICR): Up to Primary Completion Date | 21.6 (16.6 to 30.4) | 16.4 (13.8 to 22.2) |
OR was defined as a complete response (CR) or partial response (PR) according to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 recorded from randomization until disease progression or death due to any cause. CR was defined as complete disappearance of all target lesions with the exception of nodal disease. All target nodes must decrease to normal size (short axis \<10 mm). No new lesions. The PR was defined as greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. The short diameter was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No new lesions. In this outcome measure, OR was based on investigator assessment.
| Percentage of participants | Palbociclib + Letrozole | Placebo + Letrozole |
|---|---|---|
| Percentage of Participants With Objective Response (OR) Based on Investigator Assessment: Up to Primary Completion Date | 37.3 (30.0 to 45.0) | 31.6 (24.7 to 39.1) |
OR was defined as a complete response (CR) or partial response (PR) according to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 recorded from randomization until disease progression or death due to any cause. CR was defined as complete disappearance of all target lesions with the exception of nodal disease. All target nodes must decrease to normal size (short axis \<10 mm). No new lesions. The PR was defined as greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. The short diameter was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No new lesions. In this outcome measure, OR was based on investigator assessment.
| Percentage of participants | Palbociclib + Letrozole | Placebo + Letrozole |
|---|---|---|
| Percentage of Participants With Objective Response (OR) Based on Investigator Assessment (Participants With Measurable Disease at Baseline): Up to Primary Completion Date | 43.4 (35.2 to 51.9) | 38.0 (30.0 to 46.5) |
OR was defined as a complete response (CR) or partial response (PR) according to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 recorded from randomization until disease progression or death due to any cause. CR was defined as complete disappearance of all target lesions with the exception of nodal disease. All target nodes must decrease to normal size (short axis \<10 mm). No new lesions. The PR was defined as greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. The short diameter was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No new lesions. In this outcome measure, OR was based on BICR.
| Percentage of participants | Palbociclib + Letrozole | Placebo + Letrozole |
|---|---|---|
| Percentage of Participants With Objective Response (OR) Based on Blinded Independent Central Review (BICR): Up to Primary Completion Date | 40.2 (32.8 to 48.0) | 33.9 (26.9 to 41.5) |
OR was defined as a complete response (CR) or partial response (PR) according to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 recorded from randomization until disease progression or death due to any cause. CR was defined as complete disappearance of all target lesions with the exception of nodal disease. All target nodes must decrease to normal size (short axis \<10 mm). No new lesions. The PR was defined as greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. The short diameter was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No new lesions. In this outcome measure, OR was based on BICR.
| Percentage of participants | Palbociclib + Letrozole | Placebo + Letrozole |
|---|---|---|
| Percentage of Participants With Objective Response (OR) Based on Blinded Independent Central Review (BICR) (Participants With Measurable Disease at Baseline): Up to Primary Completion Date | 52.3 (43.3 to 61.2) | 43.5 (34.9 to 52.4) |
DOR was defined as the time from the first documentation of objective tumor response (complete response \[CR\] or partial response \[PR\]) to the first documentation of objective tumor progression or to death due to any cause, whichever occurred first. DOR data was censored on the date of the last tumor assessment on study for participants who did not have objective tumor progression and who did not die due to any cause while on study. CR was defined as complete disappearance of all target lesions with the exception of nodal disease. All target nodes must decrease to normal size (short axis \<10 mm). No new lesions. The PR was defined as greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. The short diameter was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No new lesions. In this outcome measure, DOR was based on investigator assessment.
| Months | Palbociclib + Letrozole | Placebo + Letrozole |
|---|---|---|
| Duration of Response (DOR) Based on Investigator Assessment (Participants With Objective Disease Response): Up to Primary Completion Date | 22.4 (19.4 to 56.2) | 19.4 (13.8 to 24.4) |
DOR was defined as the time from the first documentation of objective tumor response (complete response \[CR\] or partial response \[PR\]) to the first documentation of objective tumor progression or to death due to any cause, whichever occurred first. DOR data was censored on the date of the last tumor assessment on study for participants who did not have objective tumor progression and who did not die due to any cause while on study. CR was defined as complete disappearance of all target lesions with the exception of nodal disease. All target nodes must decrease to normal size (short axis \<10 mm). No new lesions. The PR was defined as greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. The short diameter was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No new lesions. In this outcome measure, DOR was based on BICR.
| Months | Palbociclib + Letrozole | Placebo + Letrozole |
|---|---|---|
| Duration of Response (DOR) Based on Blinded Independent Central Review (BICR) (Participants With Objective Disease Response): Up to Primary Completion Date | 30.3 (19.4 to NA) | 24.9 (11.5 to 36.1) |
DC/CBR was defined as CR, PR, or stable disease (SD) \>=24 weeks according to the Response Evaluation Criteria in Solid Tumors (RECIST v1.1) recorded in the time period between randomization and disease progression or death to any cause. CR was defined as complete disappearance of all target lesions except for nodal disease. All target nodes must decrease to normal size (short axis \<10 mm). No new lesions. The PR was defined as \>=30% decrease under baseline of the sum of diameters of all target measurable lesions. The short diameter was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No new lesions. SD was defined as not qualifying for CR, PR, PD. PD is defined using RECIST v1.1 as a 20% increase in the sum of diameters of target measurable lesions above the smallest sum observed, with a minimum absolute increase of 5 mm. In this outcome measure, DC/CBR was based on investigator assessment.
| Percentage of participants | Palbociclib + Letrozole | Placebo + Letrozole |
|---|---|---|
| Percentage of Participants With Disease Control/Clinical Benefit Response (DC/CBR) Based on Investigator Assessment: Up to Primary Completion Date | 79.3 (72.4 to 85.1) | 80.1 (73.3 to 85.8) |
DC/CBR was defined as CR, PR, or stable disease (SD) \>=24 weeks according to the Response Evaluation Criteria in Solid Tumors (RECIST v1.1) recorded in the time period between randomization and disease progression or death to any cause. CR was defined as complete disappearance of all target lesions except for nodal disease. All target nodes must decrease to normal size (short axis \<10 mm). No new lesions. The PR was defined as greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. The short diameter was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No new lesions. SD was defined as not qualifying for CR, PR, PD. PD is defined using RECIST v1.1 as a 20% increase in the sum of diameters of target measurable lesions above the smallest sum observed, with a minimum absolute increase of 5 mm. In this outcome measure, DC/CBR was based on investigator assessment.
| Percentage of participants | Palbociclib + Letrozole | Placebo + Letrozole |
|---|---|---|
| Percentage of Participants With Disease Control/Clinical Benefit Response (DC/CBR) Based on Investigator Assessment (Participants With Measurable Disease at Baseline): Up to Primary Completion Date | 77.9 (70.3 to 84.4) | 79.6 (72.0 to 85.9) |
DC/CBR was defined as CR, PR, or stable disease (SD) \>=24 weeks according to the Response Evaluation Criteria in Solid Tumors (RECIST v1.1) recorded in the time period between randomization and disease progression or death to any cause. CR was defined as complete disappearance of all target lesions except for nodal disease. All target nodes must decrease to normal size (short axis \<10 mm). No new lesions. The PR was defined as greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. The short diameter was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No new lesions. SD was defined as not qualifying for CR, PR, PD. PD is defined using RECIST v1.1 as a 20% increase in the sum of diameters of target measurable lesions above the smallest sum observed, with a minimum absolute increase of 5 mm. In this outcome measure, DC/CBR was based on BICR.
| Percentage of participants | Palbociclib + Letrozole | Placebo + Letrozole |
|---|---|---|
| Percentage of Participants With Disease Control/Clinical Benefit Response (DC/CBR) Based on Blinded Independent Central Review (BICR): Up to Primary Completion Date | 76.9 (69.8 to 83.0) | 73.1 (65.8 to 79.6) |
DC/CBR was defined as CR, PR, or stable disease (SD) \>=24 weeks according to the Response Evaluation Criteria in Solid Tumors (RECIST v1.1) recorded in the time period between randomization and disease progression or death to any cause. CR was defined as complete disappearance of all target lesions except for nodal disease. All target nodes must decrease to normal size (short axis \<10 mm). No new lesions. The PR was defined as greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. The short diameter was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No new lesions. SD was defined as not qualifying for CR, PR, PD. PD is defined using RECIST v1.1 as a 20% increase in the sum of diameters of target measurable lesions above the smallest sum observed, with a minimum absolute increase of 5 mm. In this outcome measure, DC/CBR was based on BICR.
| Percentage of participants | Palbociclib + Letrozole | Placebo + Letrozole |
|---|---|---|
| Percentage of Participants With Disease Control/Clinical Benefit Response (DC/CBR) Based on Blinded Independent Central Review (BICR) (Participants With Measurable Disease at Baseline): Up to Primary Completion Date | 78.1 (70.0 to 84.9) | 71.8 (63.2 to 79.3) |
OS was defined as the time from date of randomization to date of death due to any cause. In the absence of confirmation of death, survival time was censored to last date the participant was known to be alive. OS was assessed using Kaplan-Meier methods.
| Months | Palbociclib + Letrozole | Placebo + Letrozole |
|---|---|---|
| Overall Survival (OS): Up to Primary Completion Date | 51.7 (43.0 to NA) | 51.5 (41.0 to NA) |
OS was defined as the time from date of randomization to date of death due to any cause. In the absence of confirmation of death, survival time was censored to last date the participant was known to be alive. OS was assessed using Kaplan-Meier methods.
| Months | Palbociclib + Letrozole | Placebo + Letrozole |
|---|---|---|
| Overall Survival: Up to Secondary Completion Date | 50.3 (43.0 to 63.5) | 49.7 (41.0 to 58.1) |
OS was defined as the time from date of randomization to date of death due to any cause. In the absence of confirmation of death, survival time was censored to last date the participant was known to be alive. The 1-year survival probability was estimated using the Kaplan-Meier method and a 2-sided 95% confidence interval (CI) for the log \[-log(1 year survival probability)\] was be calculated using a normal approximation, and then back transformed to give a CI for the 1-year survival probability itself. The 2-year, and 3-year survival probabilities were estimated similarly.
| Percentage of participants | Palbociclib + Letrozole | Placebo + Letrozole |
|---|---|---|
| 1-year survival probability | 92.8 (87.6 to 95.8) | 90.5 (85.0 to 94.1) |
| 2-year survival probability | 80.3 (73.3 to 85.6) | 78.0 (71.0 to 83.6) |
| 3-year survival probability | 67.1 (59.1 to 73.8) | 60.6 (52.7 to 67.5) |
An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious AE (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state. Participants were counted only once per treatment in each row.
| Participants | Palbociclib + Letrozole | Placebo + Letrozole |
|---|---|---|
| Participants with AEs | 168 | 155 |
| Participants with SAEs | 26 | 16 |
| Participants with Grade 3 or 4 AEs | 152 | 38 |
| Participants with Grade 5 AEs | 4 | 2 |
| Participants discontinued study due to AEs | 13 | 5 |
| Participants discontinued Palbociclib/Placebo or Letrozole due to AEs | 11 | 4 |
| Participants discontinued Palbociclib/Placebo due to AEs | 11 | 4 |
| Participants discontinued Letrozole due to AEs | 10 | 3 |
| Participants temporarily discontinued Palbociclib/Placebo due to AEs | 136 | 17 |
| Participants temporarily discontinued Letrozole due to AEs | 11 | 9 |
| Participants with dose reduction of Palbociclib/Placebo due to AEs | 16 | 2 |
| Participants with dose reduction and temporary discontinuations of Palbociclib/Placebo due to AEs | 38 | 2 |
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state.
| Participants | Palbociclib + Letrozole | Placebo + Letrozole |
|---|---|---|
| Participants with AEs | 168 | 155 |
| Participants with SAEs | 34 | 19 |
| Participants with Grade 3 or 4 AEs | 152 | 40 |
| Participants with Grade 5 AEs | 4 | 3 |
| Participants discontinued study due to AEs | 14 | 6 |
| Participants discontinued Palbociclib/Placebo or Letrozole due to AEs | 12 | 4 |
| Participants temporarily discontinued Palbociclib/Placebo due to AEs | 137 | 21 |
| Participants temporarily discontinued Letrozole due to AEs | 18 | 14 |
| Participants with dose reduction of Palbociclib/Placebo due to AEs | 16 | 2 |
| Participants with dose reduction and temporary discontinuations of Palbociclib/Placebo due to AEs | 38 | 2 |
An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious AE (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state. Relatedness to treatment was assessed by the investigator (Yes/No). Participants were counted only once per treatment in each row.
| Participants | Palbociclib + Letrozole | Placebo + Letrozole |
|---|---|---|
| Participants with AEs | 167 | 123 |
| Participants with SAEs | 8 | 3 |
| Participants with Grade 3 or 4 AEs | 149 | 18 |
| Participants with Grade 5 AEs | 1 | 0 |
| Participants discontinued study due to AEs | 6 | 2 |
| Participants discontinued Palbociclib/Placebo or Letrozole due to AEs | 5 | 2 |
| Participants discontinued due to AEs related to Palbociclib/Placebo | 5 | 2 |
| Participants discontinued due to AEs related to Letrozole | 1 | 0 |
| Participants temporarily discontinued Palbociclib/Placebo due to AEs | 132 | 11 |
| Participants temporarily discontinued Letrozole due to AEs | 7 | 5 |
| Participants with dose reduction of Palbociclib/Placebo due to AEs | 15 | 2 |
| Participants with dose reduction and temporary discontinuations of Palbociclib/Placebo due to AEs | 37 | 2 |
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state. Relatedness to treatment was assessed by the investigator (Yes/No). Participants were counted only once per treatment in each row.
| Participants | Palbociclib + Letrozole | Placebo + Letrozole |
|---|---|---|
| Participants with AEs | 167 | 123 |
| Participants with SAEs | 12 | 5 |
| Participants with Grade 3 or 4 AEs | 149 | 20 |
| Participants with Grade 5 AEs | 1 | 1 |
| Participants discontinued study due to AEs | 7 | 3 |
| Participants discontinued Palbociclib/Placebo or Letrozole due to AEs | 6 | 2 |
| Participants temporarily discontinued Palbociclib/Placebo due to AEs | 133 | 12 |
| Participants temporarily discontinued Letrozole due to AEs | 11 | 7 |
| Participants with dose reduction of Palbociclib/Placebo due to AEs | 15 | 2 |
| Participants with dose reduction and temporary discontinuations of Palbociclib/Placebo due to AEs | 37 | 2 |
The laboratory results were graded according to the National Cancer Institute (NCI) CTCAE v4.0 severity grade. Shift tables were provided to examine the distribution of laboratory toxicities. The following hematology parameters had met the criteria of CTCAE grade shift change from Grade \<=2 at baseline to Grade 3 or 4 post baseline: neutrophils (absolute), white blood cells, platelets, anemia and hemoglobin increased.
| Participants | Palbociclib + Letrozole | Placebo + Letrozole |
|---|---|---|
| Neutrophils (absolute) | 143 | 2 |
| White blood cells | 77 | 1 |
| Platelets | 13 | 1 |
| Anemia | 10 | 3 |
| Hemoglobin increased | 3 | 0 |
The laboratory results were graded according to the NCI CTCAE v4.0 severity grade. Shift data were provided to examine the distribution of laboratory toxicities. The following hematology parameters met the criteria of CTCAE grade shift change from Grade \<=2 at baseline to Grade 3 or 4 post baseline: neutrophils (absolute), white blood cells, platelets, anemia and hemoglobin increased.
| Participants | Palbociclib + Letrozole | Placebo + Letrozole |
|---|---|---|
| Neutrophils (Absolute) | 143 | 2 |
| White blood cells | 81 | 1 |
| Platelets | 17 | 1 |
| Anemia | 13 | 3 |
| Haemoglobin increased | 3 | 0 |
The laboratory results were graded according to the National Cancer Institute (NCI) CTCAE v4.0 severity grade. Shift tables were provided to examine the distribution of laboratory toxicities. The following chemistry parameters had met the criteria of CTCAE grade shift change from Grade \<=2 at baseline to Grade 3 or 4 post baseline: alanine aminotransferase (ALT), alkaline phosphatase, aspartate aminotransferase (AST), bilirubin (total), creatinine, hypercalcemia, hyperglycemia, hyperkalemia, hypermagnesemia, hypernatremia, hypoalbuminemia, hypocalcemia, hypoglycemia, hypokalemia, hypomagnesemia, and hyponatremia.
| Participants | Palbociclib + Letrozole | Placebo + Letrozole |
|---|---|---|
| ALT | 9 | 1 |
| Alkaline phosphatase | 0 | 2 |
| AST | 9 | 6 |
| Bilirubin (total) | 2 | 2 |
| Creatinine | 1 | 0 |
| Hypercalcemia | 1 | 2 |
| Hyperglycemia | 1 | 1 |
| Hyperkalemia | 1 | 0 |
| Hypermagnesemia | 10 | 8 |
| Hypernatremia | 2 | 1 |
| Hypoalbuminemia | 0 | 0 |
| Hypocalcemia | 1 | 1 |
| Hypoglycemia | 0 | 1 |
| Hypokalemia | 3 | 6 |
| Hypomagnesemia | 3 | 1 |
| Hyponatremia | 11 | 2 |
The laboratory results were graded according to the NCI CTCAE v4.0 severity grade. Shift tables were provided to examine the distribution of laboratory toxicities. The following chemistry parameters had met the criteria of CTCAE grade shift change from Grade \<=2 at baseline to Grade 3 or 4 post baseline: ALT, alkaline phosphatase, AST, bilirubin (total), creatinine, hypercalcemia, hyperglycemia, hyperkalemia, hypermagnesemia, hypernatremia, hypoalbuminemia, hypocalcemia, hypoglycemia, hypokalemia, hypomagnesemia, and hyponatremia.
| Participants | Palbociclib + Letrozole | Placebo + Letrozole |
|---|---|---|
| ALT | 10 | 1 |
| Alkaline phosphatase | 0 | 2 |
| AST | 9 | 6 |
| Bilirubin Total | 3 | 2 |
| Creatinine | 1 | 0 |
| Hypercalcemia | 1 | 2 |
| Hyperglycemia | 2 | 1 |
| Hyperkalemia | 0 | 0 |
| Hypermagnesemia | 9 | 9 |
| Hypernatremia | 2 | 1 |
| Hypoalbuminemia | 0 | 0 |
| Hypocalcemia | 1 | 1 |
| Hypoglycemia | 0 | 1 |
| Hypokalemia | 3 | 6 |
| Hypomagnesemia | 4 | 1 |
| Hyponatremia | 10 | 2 |
Summary of palbociclib trough concentrations.
| ng/mL | Palbociclib + Letrozole |
|---|---|
| Cycle 1 | 81.1 ± 29 |
| Cycle 2 | 77.4 ± 43 |
| Average trough concentration | 80.2 ± 36 |
The Functional Assessment of Cancer Therapy (FACT) is a modular approach to assess participant health related quality of life using a "core" set of questions (FACT-G) as well as a cancer site specific module. The FACT-G was a 27-item compilation of general questions divided into 4 domains: Physical Well Being, Social/Family Well Being, Emotional Well Being, and Functional Well Being. The FACT-B consists of the FACT-G (27 items) and a breast specific module: a 10-item instrument designed to assess participant concerns relating to breast cancer. For all questions, participants were asked to respond to a 5-level scale ranging from 0=Not at all to 4=Very much. FACT-B total score = FACT-G + Breast Cancer Subscale. As each of the items ranges from 0-4, the range of possible scores is 0-148, with 0 being the worst possible score and 148 the best. A positive change of the total score indicated improvement from baseline and a negative change indicated deterioration.
| Units on a scale | Palbociclib + Letrozole | Placebo + Letrozole |
|---|---|---|
| Cycle 2 Day 1 | 1.618 (-0.15 to 3.39) | 1.021 (-0.74 to 2.78) |
| Cycle 3 Day 1 | 1.441 (-0.32 to 3.20) | 0.850 (-0.90 to 2.60) |
| Cycle 5 Day 1 | 1.087 (-0.69 to 2.86) | 0.510 (-1.25 to 2.27) |
| Cycle 7 Day 1 | 0.732 (-1.07 to 2.53) | 0.169 (-1.62 to 1.96) |
| Cycle 9 Day 1 | 0.378 (-1.48 to 2.23) | -0.171 (-2.02 to 1.68) |
| Cycle 11 Day 1 | 0.024 (-1.90 to 1.95) | -0.512 (-2.44 to 1.41) |
| Cycle 13 Day 1 | -0.331 (-2.34 to 1.68) | -0.852 (-2.88 to 1.17) |
| Cycle 15 Day 1 | -0.685 (-2.80 to 1.43) | -1.193 (-3.33 to 0.95) |
| Cycle 17 Day 1 | -1.039 (-3.27 to 1.19) | -1.534 (-3.80 to 0.74) |
| Cycle 19 Day 1 | -1.393 (-3.75 to 0.96) | -1.874 (-4.29 to 0.54) |
| Cycle 21 Day 1 | -1.748 (-4.24 to 0.75) | -2.215 (-4.78 to 0.35) |
| Cycle 23 Day 1 | -2.102 (-4.74 to 0.54) | -2.555 (-5.28 to 0.17) |
| Cycle 25 Day 1 | -2.456 (-5.24 to 0.33) | -2.896 (-5.79 to 0.00) |
| Cycle 27 Day 1 | -2.810 (-5.76 to 0.13) | -3.326 (-6.31 to -0.16) |
| Cycle 29 Day 1 | -3.165 (-6.27 to -0.06) | -3.577 (-6.83 to -0.33) |
| Cycle 31 Day 1 | -3.519 (-6.79 to -0.25) | -3.918 (-7.35 to -0.48) |
| Cycle 33 Day 1 | -3.873 (-7.31 to -0.43) | -4.258 (-7.88 to -0.64) |
| Cycle 35 Day 1 | -4.227 (-7.84 to -0.62) | -4.599 (-8.41 to -0.79) |
| Cycle 37 Day 1 | -4.582 (-8.37 to -0.80) | -4.939 (-8.95 to -0.93) |
| Cycle 39 Day 1 | -4.936 (-8.90 to -0.97) | -5.280 (-9.48 to -1.08) |
| Cycle 41 Day 1 | -5.290 (-9.43 to -1.15) | -5.620 (-10.02 to -1.22) |
| Cycle 43 Day 1 | -5.644 (-9.97 to -1.32) | -5.961 (-10.56 to -1.36) |
| Cycle 45 Day 1 | -5.999 (-10.50 to -1.50) | -6.301 (-11.10 to -1.50) |
| Cycle 47 Day 1 | -6.353 (-11.04 to -1.67) | -6.642 (-11.64 to -1.64) |
| Cycle 49 Day 1 | -6.707 (-11.58 to -1.84) | -6.983 (-12.18 to -1.78) |
| Cycle 51 Day 1 | -7.061 (-12.12 to -2.00) | -7.323 (-12.73 to -1.92) |
| Cycle 53 Day 1 | -7.416 (-12.66 to -2.17) | -7.664 (-13.27 to -2.05) |
| Cycle 55 Day 1 | -7.770 (-13.20 to -2.34) | -8.004 (-13.82 to -2.19) |
| Cycle 57 Day 1 | -8.124 (-13.74 to -2.51) | -8.345 (-14.37 to -2.32) |
| Cycle 59 Day 1 | -8.478 (-14.29 to -2.67) | -8.685 (-14.91 to -2.46) |
| Cycle 61 Day 1 | -8.833 (-14.83 to -2.84) | -9.026 (-15.46 to -2.59) |
| Cycle 63 Day 1 | -9.187 (-15.37 to -3.00) | -9.367 (-16.01 to -2.72) |
| Cycle 65 Day 1 | -9.541 (-15.92 to -3.16) | -9.707 (-16.56 to -2.86) |
The EQ-5D is a 6-item instrument designed to assess health status in terms of a single index value or utility score. It consists of 5 descriptors of current health state (mobility, self care, usual activities, pain/discomfort, and anxiety/depression); a participant was asked to rate each state on a 3 level scale (1=no problem, 2=some problem, and 3=extreme problem) with higher levels indicating greater severity/impairment.
| Units on a scale | Palbociclib + Letrozole | Placebo + Letrozole |
|---|---|---|
| Cycle 2 Day 1 | 0.013 (-0.01 to 0.03) | 0.014 (-0.01 to 0.03) |
| Cycle 3 Day 1 | 0.012 (-0.01 to 0.03) | 0.011 (-0.01 to 0.03) |
| Cycle 5 Day 1 | 0.010 (-0.01 to 0.03) | 0.005 (-0.01 to 0.03) |
| Cycle 7 Day 1 | 0.008 (-0.01 to 0.03) | 0.000 (-0.02 to 0.02) |
| Cycle 9 Day 1 | 0.006 (-0.02 to 0.03) | -0.006 (-0.03 to 0.02) |
| Cycle 11 Day 1 | 0.004 (-0.02 to 0.03) | -0.012 (-0.04 to 0.01) |
| Cycle 13 Day 1 | 0.02 (-0.02 to 0.03) | -0.017 (-0.04 to 0.01) |
| Cycle 15 Day 1 | 0.000 (-0.03 to 0.03) | -0.023 (-0.05 to 0.01) |
| Cycle 17 Day 1 | -0.002 (-0.03 to 0.03) | -0.029 (-0.06 to 0.00) |
| Cycle 19 Day 1 | -0.004 (-0.04 to 0.03) | -0.034 (-0.07 to 0.00) |
| Cycle 21 Day 1 | -0.006 (-0.04 to 0.03) | -0.040 (-0.08 to 0.00) |
| Cycle 23 Day 1 | -0.008 (-0.05 to 0.03) | -0.045 (-0.08 to -0.01) |
| Cycle 25 Day 1 | -0.010 (-0.05 to 0.03) | -0.051 (-0.09 to -0.01) |
| Cycle 27 Day 1 | -0.012 (-0.05 to 0.03) | -0.057 (-0.10 to -0.01) |
| Cycle 29 Day 1 | -0.014 (-0.06 to 0.03) | -0.062 (-0.11 to -0.02) |
| Cycle 31 Day 1 | -0.016 (-0.06 to 0.03) | -0.068 (-0.12 to -0.02) |
| Cycle 33 Day 1 | -0.018 (-0.07 to 0.03) | -0.074 (-0.13 to -0.02) |
| Cycle 35 Day 1 | -0.020 (-0.07 to 0.03) | -0.079 (-0.13 to -0.02) |
| Cycle 37 Day 1 | -0.022 (-0.08 to 0.03) | -0.085 (-0.14 to -0.03) |
| Cycle 39 Day 1 | -0.024 (-0.08 to 0.03) | -0.090 (-0.15 to -0.03) |
| Cycle 41 Day 1 | -0.027 (-0.09 to 0.03) | -0.096 (-0.16 to -0.03) |
| Cycle 43 Day 1 | -0.029 (-0.09 to 0.04) | -0.102 (-0.17 to -0.03) |
| Cycle 45 Day 1 | -0.031 (-0.10 to 0.04) | -0.107 (-0.18 to -0.04) |
| Cycle 47 Day 1 | -0.033 (-0.10 to 0.04) | -0.113 (-0.19 to -0.04) |
| Cycle 49 Day 1 | -0.035 (-0.11 to 0.04) | -0.119 (-0.20 to -0.04) |
| Cycle 51 Day 1 | -0.037 (-0.11 to 0.04) | -0.124 (-0.20 to -0.04) |
| Cycle 53 Day 1 | -0.039 (-0.12 to 0.04) | -0.130 (-0.21 to -0.05) |
| Cycle 55 Day 1 | -0.041 (-0.12 to 0.04) | -0.136 (-0.22 to -0.05) |
| Cycle 57 Day 1 | -0.043 (-0.13 to 0.04) | -0.141 (-0.23 to -0.05) |
| Cycle 59 Day 1 | -0.045 (-0.13 to 0.04) | -0.147 (-0.24 to -0.05) |
| Cycle 61 Day 1 | -0.047 (-0.14 to 0.04) | -0.152 (-0.25 to -0.06) |
| Cycle 63 Day 1 | -0.049 (-0.14 to 0.04) | -0.158 (-0.26 to -0.06) |
| Cycle 65 Day 1 | -0.051 (-0.15 to 0.04) | -0.164 (-0.27 to -0.06) |
The EQ VAS recorded the participant's self rated questionnaire to assess generic health status on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state). Published weights were available that allow for the creation of a single summary score.
| Units on a scale | Palbociclib + Letrozole | Placebo + Letrozole |
|---|---|---|
| Cycle 2 Day 1 | 3.047 (1.53 to 4.57) | 1.861 (0.35 to 3.37) |
| Cycle 3 Day 1 | 3.125 (1.62 to 4.63) | 1.815 (0.32 to 3.31) |
| Cycle 5 Day 1 | 3.279 (1.79 to 4.77) | 1.724 (0.24 to 3.21) |
| Cycle 7 Day 1 | 3.434 (1.94 to 4.92) | 1.634 (0.16 to 3.11) |
| Cycle 9 Day 1 | 3.589 (2.09 to 5.09) | 1.543 (0.05 to 3.03) |
| Cycle 11 Day 1 | 3.743 (2.22 to 5.26) | 1.452 (-0.06 to 2.97) |
| Cycle 13 Day 1 | 3.898 (2.35 to 5.45) | 1.361 (-0.19 to 2.92) |
| Cycle 15 Day 1 | 4.052 (2.46 to 5.65) | 1.271 (-0.34 to 2.88) |
| Cycle 17 Day 1 | 4.207 (2.56 to 5.85) | 1.180 (-0.49 to 2.85) |
| Cycle 19 Day 1 | 4.362 (2.65 to 6.07) | 1.089 (-0.65 to 2.83) |
| Cycle 21 Day 1 | 4.516 (2.74 to 6.29) | 0.998 (-0.83 to 2.82) |
| Cycle 23 Day 1 | 4.671 (2.82 to 6.52) | 0.908 (-1.01 to 2.82) |
| Cycle 25 Day 1 | 4.826 (2.89 to 6.76) | 0.817 (-1.20 to 2.83) |
| Cycle 27 Day 1 | 4.980 (2.96 to 7.00) | 0.726 (-1.39 to 2.84) |
| Cycle 29 Day 1 | 5.135 (3.02 to 7.25) | 0.635 (-1.59 to 2.86) |
| Cycle 31 Day 1 | 5.289 (3.08 to 7.50) | 0.545 (-1.79 to 2.88) |
| Cycle 33 Day 1 | 5.444 (3.13 to 7.76) | 0.454 (-1.99 to 2.90) |
| Cycle 35 Day 1 | 5.599 (3.18 to 8.02) | 0.363 (-2.20 to 2.93) |
| Cycle 37 Day 1 | 5.753 (3.23 to 8.28) | 0.272 (-2.42 to 2.96) |
| Cycle 39 Day 1 | 5.908 (3.28 to 8.54) | 0.182 (-2.63 to 2.99) |
| Cycle 41 Day 1 | 6.063 (3.32 to 8.81) | 0.091 (-2.85 to 3.03) |
| Cycle 43 Day 1 | 6.217 (3.36 to 9.07) | 0.000 (-3.06 to 3.06) |
| Cycle 45 Day 1 | 6.372 (3.40 to 9.34) | -0.091 (-3.28 to 3.10) |
| Cycle 47 Day 1 | 6.526 (3.44 to 9.61) | -0.181 (-3.51 to 3.14) |
| Cycle 49 Day 1 | 6.681 (3.48 to 9.89) | -0.272 (-3.73 to 3.18) |
| Cycle 51 Day 1 | 6.836 (3.51 to 10.16) | -0.363 (-3.95 to 3.23) |
| Cycle 53 Day 1 | 6.990 (3.55 to 10.43) | -0.454 (-4.18 to 3.27) |
| Cycle 55 Day 1 | 7.145 (3.58 to 10.71) | -0.544 (-4.40 to 3.31) |
| Cycle 57 Day 1 | 7.300 (3.61 to 10.99) | -0.635 (-4.63 to 3.36) |
| Cycle 59 Day 1 | 7.454 (3.64 to 11.26) | -0.726 (-4.86 to 3.41) |
| Cycle 61 Day 1 | 7.609 (3.68 to 11.54) | -0.817 (-5.08 to 3.45) |
| Cycle 63 Day 1 | 7.763 (3.71 to 11.82) | -0.907 (-5.31 to 3.50) |
| Cycle 65 Day 1 | 7.918 (3.74 to 12.10) | -0.998 (-5.54 to 3.55) |
Archived formalin-fixed paraffin embedded (FFPE) specimen from the original diagnostic tumor tissue was collected and sent to the sponsor-designated central laboratories for assessment of Ki67 associated with sensitivity and/or resistance to Palbociclib.
| Percentage of Ki67 positive cells | Palbociclib + Letrozole | Placebo + Letrozole |
|---|---|---|
| Median Baseline Percent (%) Positive Cells for Ki67 | 30.0 (0 to 95) | 27.5 (0 to 95) |
Archived formalin-fixed paraffin embedded (FFPE) specimen from the original diagnostic tumor tissue was collected and sent to the sponsor-designated central laboratories for assessment of ER associated with sensitivity and/or resistance to Palbociclib.
| Participants | Palbociclib + Letrozole | Placebo + Letrozole |
|---|---|---|
| Positive | 152 | 162 |
| Negative | 2 | 1 |
| Unknown | 14 | 8 |
Collected over Up to 28 days after last dose of study drug or start of new treatment (data collection maximum up to approximately 119 months after randomization). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Palbociclib + Letrozole | 102/168 (60.7%) | 34/168 (20.2%) | 168/168 (100%) |
| Placebo + Letrozole | 126/171 (73.7%) | 19/171 (11.1%) | 143/171 (83.6%) |
| Event | Palbociclib + Letrozole | Placebo + Letrozole |
|---|---|---|
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 3/168 | 0/171 |
| CataractEye disorders | 2/168 | 0/171 |
| PyrexiaGeneral disorders | 2/168 | 0/171 |
| PneumoniaInfections and infestations | 2/168 | 2/171 |
| Urinary tract infectionInfections and infestations | 2/168 | 2/171 |
| Ankle fractureInjury, poisoning and procedural complications | 2/168 | 0/171 |
| Platelet count decreasedInvestigations | 2/168 | 1/171 |
| Neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 2/168 | 0/171 |
| HypercalcaemiaMetabolism and nutrition disorders | 0/168 | 2/171 |
| AnaemiaBlood and lymphatic system disorders | 1/168 | 0/171 |
| Event | Palbociclib + Letrozole | Placebo + Letrozole |
|---|---|---|
| Neutrophil count decreasedInvestigations | 112/168 | 19/171 |
| White blood cell count decreasedInvestigations | 108/168 | 17/171 |
| NeutropeniaBlood and lymphatic system disorders | 75/168 | 12/171 |
| Platelet count decreasedInvestigations | 73/168 | 7/171 |
| AnaemiaBlood and lymphatic system disorders | 69/168 | 16/171 |
| Aspartate aminotransferase increasedInvestigations | 61/168 | 49/171 |
| Alanine aminotransferase increasedInvestigations | 60/168 | 58/171 |
| LeukopeniaBlood and lymphatic system disorders | 51/168 | 9/171 |
| CoughRespiratory, thoracic and mediastinal disorders | 28/168 | 22/171 |
| Electrocardiogram QT prolongedInvestigations | 27/168 | 16/171 |
| Age, Continuous(years) | Palbociclib + Letrozole | Placebo + Letrozole | Total |
|---|---|---|---|
| Mean | 53.8 ± 8.5 | 53.7 ± 9.1 | 53.8 ± 8.8 |
| Sex: Female, Male(Participants) | Palbociclib + Letrozole | Placebo + Letrozole | Total |
|---|---|---|---|
| Female | 169 | 171 | 340 |
| Male | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Palbociclib + Letrozole | Placebo + Letrozole | Total |
|---|---|---|---|
| Asian | 169 | 171 | 340 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Ran from Mar 2015 to primary completion in Aug 2020, 65 months.
Results were first posted in Nov 2021, 1 year 2 months after primary completion.
Of 272 industry-sponsored phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's 65 months is above that.
Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Palbociclib